Key result
TAVI with ACURATE neo had higher moderate/severe paravalvular regurgitation but lower new pacemaker implantation.
Why the study?
Several supra-annular self-expanding systems are available for TAVI, but comparative data from large-scale multicenter studies are scant.
Do different self-expanding devices (ACURATE neo vs Evolut R vs Evolut PRO) affect the rates of paravalvular regurgitation, pacemaker implantation, and survival in patients undergoing transfemoral TAVI for severe aortic stenosis?
Observational (n=5,175)
Yes
Do different self-expanding devices (ACURATE neo vs Evolut R vs Evolut PRO) affect the rates of paravalvular regurgitation, pacemaker implantation, and survival in patients undergoing transfemoral TAVI for severe aortic stenosis?
In patients undergoing transfemoral TAVI, the ACURATE neo valve is associated with higher rates of paravalvular regurgitation but lower rates of new pacemaker implantation compared to the Evolut R and Evolut PRO valves, with comparable short-term mortality.
Answers are grounded in this paper and cite their sources.
ACURATE neo trade-offs warrant caution in device selection; leaves open optimal self-expanding TAVI choice pending randomized data.
OBJECTIVE: Several supra-annular self-expanding transcatheter systems are commercially available for transcatheter aortic valve implantation (TAVI). Comparative data in large-scale multicenter studies are scant. METHODS: This study included a total of 5175 patients with severe aortic stenosis undergoing TAVI with the ACURATE neo (n = 1095), Evolut R (n = 3365), or Evolut PRO (n = 715) by a transfemoral approach at five high-volume centers. Propensity score matching resulted in 654 triplets. Outcomes are reported according to the Valve Academic Research Consortium-3 (VARC-3) consensus. RESULTS: Moderate or severe paravalvular regurgitation (PVR) occurred significantly more often in the ACURATE neo group (5.2%) than in the Evolut R (1.8%) and Evolut PRO (3.3%) groups (p = 0.003). The rates of major vascular-/access-related complications (4.6%, 3.8%, and 5.0%; p = 0.56), type 3 or 4 bleeding (3.2%, 2.1%, and 4.1%; p = 0.12), and 30-day mortality (2.4%, 2.6%, and 3.7%; p = 0.40) were comparable. The rate of new permanent pacemaker implantation (PPI) was significantly lower in the ACURATE neo group (9.5%, 17.6%, and 16.8%; p < 0.001). Independent predictors for 2-year survival were a Society of Thoracic Surgeons (STS) risk score ≥5%, diabetes mellitus, a glomerular filtration rate <30 ml/min, baseline mean transvalvular gradient ≤ 30 mm Hg, treating center, and relevant PVR. CONCLUSION: In this multicenter study, TAVI with the ACURATE neo, Evolut R, or Evolut PRO was feasible and safe. The rate of relevant PVR was more frequent after the ACURATE neo implantation, with, however, lower rates of PPI. Two-year survival was mainly driven by baseline comorbidities.
No takes yet. Share an insight, caveat, or question.
Wienemann et al. (2022) conducted an observational in severe aortic stenosis (n=5,175). ACURATE neo vs. Evolut R and Evolut PRO was evaluated on Moderate or severe paravalvular regurgitation (PVR) (p=0.003). TAVI with ACURATE neo had higher moderate/severe paravalvular regurgitation but lower new pacemaker implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: